LPL Financial LLC Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

LPL Financial LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,500 shares of the company's stock after buying an additional 3,963 shares during the period. LPL Financial LLC's holdings in IDEXX Laboratories were worth $15,748,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Bamco Inc. NY grew its holdings in IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after acquiring an additional 82,264 shares during the period. Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock worth $472,865,000 after purchasing an additional 414,802 shares during the period. GAMMA Investing LLC grew its stake in shares of IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after purchasing an additional 916,898 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of IDEXX Laboratories by 18.6% in the 4th quarter. Northern Trust Corp now owns 912,874 shares of the company's stock valued at $377,419,000 after purchasing an additional 143,369 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research analyst reports. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target for the company. Morgan Stanley set a $722.00 price target on IDEXX Laboratories and gave the stock an "overweight" rating in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a report on Monday. Finally, Leerink Partners lifted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $623.56.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $25.87 during mid-day trading on Thursday, reaching $650.06. 798,751 shares of the company's stock were exchanged, compared to its average volume of 789,096. The company has a quick ratio of 0.81, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The company has a market cap of $52.00 billion, a price-to-earnings ratio of 54.13, a PEG ratio of 4.03 and a beta of 1.49. The company has a 50-day simple moving average of $542.32 and a two-hundred day simple moving average of $477.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%. IDEXX Laboratories's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.44 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.